Could a simple pause in a common labor drug make birth safer?
NCT ID NCT03991091
Summary
This large study tested whether stopping the labor-inducing drug oxytocin once active labor begins could reduce health problems in newborns. It involved over 2,400 women in France who were already receiving oxytocin. Researchers compared outcomes for babies whose mothers either continued the standard oxytocin treatment or had it stopped at 6 cm dilation, to see if less drug exposure led to fewer complications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEONATAL MORBIDITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
hospital Cochin; port royal Maternity unit
Paris, 75014, France
Conditions
Explore the condition pages connected to this study.